Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript
Bausch + Lomb (BLCO) reported Q2 2026 revenue of $1.394B, up 8% constant currency, and adjusted EBITDA of $246M, up 28%, with margin at 17.6%. Surgical, Pharmaceuticals, and Vision Care all grew. Full-year guidance raised to revenue $5.440B-$5.540B and adjusted EBITDA $1.025B-$1.075B. Net leverage fell to 4.7x.
How this was made
The 30-second read
Why it matters
Raised full-year revenue and adjusted EBITDA guidance, higher adjusted EBITDA margin, and improved cash flow and leverage reduction are likely to drive upward earnings revisions. However, the enVista Beyond investigational lens narrowly missing pivotal performance targets introduces regulatory and timeline uncertainty for a key surgical program.
Market read
Traders can act on the raised full-year guidance and margin/cash-flow improvements, while monitoring pipeline/regulatory risk from the enVista Beyond pivotal-study outcome.
What to watch
Leverage reduction and cash flow are supportive, but investors may discount operating leverage quality if working-capital improvements reverse; also consumer eye-care demand is described as fluctuating with gasoline prices, which could pressure near-term volume.
Background
Bausch + Lomb held its Q2 2026 earnings call, covering segment performance (Pharmaceuticals, Vision Care, Surgical), pipeline updates, and full-year guidance changes.
Ticker impact
Bausch + Lomb reported Q2 2026 revenue of $1.394B, raised full-year revenue guidance to $5.44B-$5.54B, and lifted adjusted EBITDA guidance to $1.025B-$1.075B.
Bias toward upside revisions and multiple support if investors focus on raised guidance and leverage reduction; near-term volatility possible around enVista Beyond regulatory engagement and timing.
The article provides multiple quantified beats and upward guidance (revenue, adjusted EBITDA, margin, cash flow, leverage) alongside a specific clinical performance miss requiring further regulatory engagement, which can temper sentiment and affect surgical/dry-eye pipeline expectations.
Market effects
Signals improving profitability and cash conversion in eye-care and surgical ophthalmology, potentially supporting sentiment for peers with similar dry-eye and premium IOL exposure.
Primarily US-listed large-cap healthcare sentiment; could influence US medtech/ophthalmology positioning into the next earnings cycle.
Constant-currency growth and international expansion commentary may matter for global ophthalmology demand expectations, though guidance is company-specific.
Counterpoint
The enVista Beyond pivotal study narrowly missing predefined performance targets could delay regulatory milestones, offsetting the positive guidance narrative for surgical premium IOL growth.
Key entities
- companyBausch + Lomb
Reported Q2 2026 results and raised full-year guidance; discussed surgical and dry-eye pipeline progress and an enVista Beyond pivotal-study miss.
- product_programenVista Beyond
Investigational lens pivotal study narrowly missed predefined performance targets, requiring further regulatory engagement.
- productMiebo
Dry eye treatment with 44% constant-currency revenue growth in the quarter and management expectation to become a branded industry leader.
- product_programELIOS
Implant-free MIGS excimer laser; company filed an FDA submission and expects clinical readouts in the second half of 2026.
- digital_health_platformOrphia
AI-powered digital health platform launched to reduce operational burden between physicians and patients.
